Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • PI3K
    (10)
  • Apoptosis
    (3)
  • mTOR
    (2)
  • Akt
    (1)
  • HDAC
    (1)
  • PI4K
    (1)
  • S6 Kinase
    (1)
  • Others
    (4)
Filter
Search Result
Results for "

pi3kδ-in-3

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    14
    TargetMol | Inhibitors_Agonists
PI3Kδ-IN-3
TC KHNS 11
T262521431540-99-6
PI3Kδ-IN-3 (TC KHNS 11) is a PI3Kδ inhibitor with an IC50 value of 9 nM.PI3Kδ-IN-3 has a favorable pharmacokinetic profile and inhibits B cell function.
  • Inquiry Price
6-8 weeks
Size
QTY
pi3kδ/γ-in-3
T630782730151-31-0
PI3Kδ γ-IN-3 (Compound 58) is an orally active dual inhibitor of PI3Kδ (IC50: 1 nM) and PI3Kγ (IC50: 16 nM), effective in inducing apoptosis of tumor cells and applicable to B-cell malignant tumor studies.
  • Inquiry Price
6-8 weeks
Size
QTY
Fimepinostat
PI3K HDAC Inhibitor, CUDC-907, CUDC 907
T20781339928-25-4
Fimepinostat (CUDC 907) is an orally bioavailable inhibitor of both phosphoinositide 3-kinase (PI3K) class I and pan-histone deacetylase (HDAC) enzymes, with potential antineoplastic activity. Upon oral administration, CUDC-907 inhibits the activity of both PI3K class I isoforms and HDAC, thereby preventing the activation of the PI3K-AKT-mTOR signal transduction pathway that is often overactivated in many cancer cell types.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
Copanlisib
BAY 80-6946
T63221032568-63-0
Copanlisib (BAY 80-6946) is a phosphoinositide 3-kinase (PI3K) inhibitor with potential antineoplastic activity. By inhibiting the PI3K signaling pathway, Copanlisib may impede tumor cell growth and survival in certain tumor populations. Dysregulated PI3K signaling, often linked to tumorigenesis, may also contribute to tumor resistance to various antineoplastic agents.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
PI4KIIIbeta-IN-9
T124691429624-84-9
PI4KIIIbeta-IN-9 is a potent inhibitor of PI4KIIIβ [IC50 of 7 nM].
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
Bimiralisib
PQR309, PI3K-IN-2, 5-(4,6-dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine
T22651225037-39-7
Bimiralisib (PI3K-IN-2) is an orally bioavailable pan inhibitor of PI3K and inhibitor of the mTOR, with potential antineoplastic activity. PI3K-IN-2 inhibits the PI3K kinase isoforms alpha, beta, gamma and delta and, to a lesser extent, mTOR kinase, which may result in tumor cell apoptosis and growth inhibition in cells overexpressing PI3K mTOR. Activation of the PI3K mTOR pathway promotes cell growth, survival, and resistance to both chemotherapy and radiotherapy.
  • Inquiry Price
Size
QTY
Pilaralisib
XL-147, SAR245408
T2365934526-89-3
Pilaralisib (XL-147) is an orally available small molecule that selectively inhibits the activity of phosphoinositide-3 kinase (PI3K). Pilaralisib has been used in trials studying the treatment of Cancer, Lymphoma, Solid Tumors, Glioblastoma, and Breast Cancer, among others.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
(S)-PI3Kα-IN-4
(S)-PI3Kα-IN-4
T354882322293-84-3
(S)-PI3Kα-IN-4, a potent inhibitor of PI3Kα with an IC50 of 2.3 nM, demonstrates 38.3-, 4.25-, and 4.93-fold selectivity over PI3Kβ, PI3Kδ, and PI3Kγ, respectively, and is suitable for cancer research[1]. (S)-PI3Kα-IN-4 (compound 11) is a quinazolin-4(3H)-one derivative with 2-substituted-N-methylpropanamide substitution[1].
  • Inquiry Price
6-8 weeks
Size
QTY
FD223
T355312050524-24-6
FD223 is a potent, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor with a marked affinity (IC50=1 nM), demonstrating notable selectivity against other isoforms (IC50s: α=51 nM, β=29 nM, γ=37 nM). This compound effectively suppresses the proliferation of acute myeloid leukemia (AML) cell lines by inhibiting p-AKT Ser473, thereby inducing G1 phase cell cycle arrest. FD223 holds promise for leukemia research, particularly in AML[1].
  • Inquiry Price
6-8 weeks
Size
QTY
DS-7423
T360831222104-37-1
DS-7423 is a dual PI3K and mTOR inhibitor, with IC50 values of 15.6 nM and 34.9 nM for PI3Kα and mTOR, respectively, and exhibits anti-tumor activity[1][2]. It increases TP53 expression, the level of p-TP53 on Ser-46, and induces apoptosis-related TP53 target genes (TP53AIP1 and PUMA) in OCCC cells[1]. DS-7423 also inhibits other isoforms of class I PI3K with IC50 values of 1,143 nM for PI3Kβ, 249 nM for PI3Kγ, and 262 nM for PI3Kδ[2]. [1]. Katsutoshi Oda, et al. Characterization of TP53 and PI3K signaling pathways as molecular targets in gynecologic malignancies. J Obstet Gynaecol Res. 2016 Jul;42(7):757-62. [2]. Tomoko Kashiyama, et al. Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K mTOR inhibitor DS-7423. PLoS One. 2014 Feb 4;9(2):e87220.
  • Inquiry Price
Size
QTY
PI3Kδ-IN-9
PI3Kδ-IN-9
T395922135922-40-4
PI3Kδ-IN-9 is a selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor with an IC50 value of 3.8 nM.
  • Inquiry Price
Size
QTY
PI3K/AKT-IN-1
T629973033069-84-7
PI3K AKT-IN-1 is a dual PI3K and AKT inhibitor with anti-cancer activity. It inhibits PI3Kγ, PI3Kδ, and AKT, suppressing the PI3K AKT pathway and inducing caspase 3-dependent apoptosis, suitable for cancer research.
  • Inquiry Price
10-14 weeks
Size
QTY
Linperlisib
PI3Kδ-IN-2
T63301702816-75-8
Linperlisib (PI3Kδ-IN-2) is a potent and selective inhibitor of PI3Kδ
  • Inquiry Price
Size
QTY
PI3K-IN-47
T78853
PI3K-IN-47 (Compound 27) is a potent bivalent inhibitor targeting the phosphoinositide 3-kinases (PI3K) family, with IC50 values of 0.44 nM for PI3Kα, and 7.18 nM, 13.92 nM, and 22.83 nM for PI3Kβ, PI3Kγ, and PI3Kδ respectively. It induces G1 phase cell cycle arrest and exhibits anti-neoplastic properties by restraining colony formation and cell migration. Additionally, PI3K-IN-47 has demonstrated the ability to suppress tumor growth in HGC-27 xenograft mouse models [1].
  • Inquiry Price
Size
QTY